<DOC>
	<DOCNO>NCT02328807</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy focal ( target ) Radio-Frequency Ablation ( RFA ) men low intermediate-risk , clinically localized prostate cancer .</brief_summary>
	<brief_title>Focal Prostate Radio-Frequency Ablation</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 18 year age old Diagnosis adenocarcinoma prostate , confirm H.L . Moffitt Cancer Center review No prior treatment prostate cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 or1 Prostate Cancer Clinical Stage T2a PSA &lt; 10 ng/ml ( prostatic specific antigen ( PSA ) level prompt initial prostate biopsy ) Prostate size &lt; 60 cc transrectal ultrasound Preenrollment biopsy parameter ( per H.L . Moffitt C.C . review ) : Minimum 10 biopsy core ; Gleason score 6 aor 7 ; Unilateral cancer ( rightsided leftsided , bilateral ) . Men le 18 year age Medically unfit anesthesia Histology adenocarcinoma Biopsy meet inclusion criterion Men receive hormonal manipulation ( antiandrogens ; Luteinizing Hormone Releasing Hormone ( LHRH ) agonist ; 5alphareductase inhibitor ) within previous 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>prostate</keyword>
	<keyword>ENCAGEâ„¢</keyword>
	<keyword>focal bipolar radiofrequency ablation</keyword>
	<keyword>radiofrequency ablation ( RFA )</keyword>
	<keyword>radiotherapy</keyword>
</DOC>